atrial fibrillation

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation

By MedXY 05/15/2026

This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality in patients with atrial fibrillation.

Cardiology Diabetes & Endocrinology news

Subclinical Hyperthyroidism Carries Measurable Risks of Atrial Fibrillation, Heart Failure, and Death in Primary Care

By MedXY 05/10/2026

A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongly suppressed TSH.

Cardiology Neurology news

Late-Life Stroke in ARIC Was More Often Embolic, and Atrial Disease Explained Much of the Risk

By MedXY 05/01/2026

In ARIC, ischemic stroke at age 80 years or older was more often embolic than thrombotic. Atrial fibrillation and left atrial disease explained much of the age effect, and adding embolic factors improved prediction.

Cardiology news

Standard-Dose DOACs Outperform Warfarin More Strongly in Asian Than Non-Asian Patients With Atrial Fibrillation

By MedXY 04/30/2026

In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored over lower-dose regimens in Asians.

Cardiology news

Pre-Treatment Fibrin Clot Lysis Time Predicts Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulants

By MedXY 04/28/2026

Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.

Cardiology Gastroenterology news

Unraveling the Gut-Heart Connection: How Leaky Gut Fuels Atrial Fibrillation in Aging

By MedXY 04/22/2026

Researchers identify JNK2 as a key mediator in gut-heart crosstalk, linking intestinal permeability to atrial fibrillation pathogenesis through inflammatory stress signals, offering new therapeutic targets.

Cardiology news

AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial

By MedXY 04/15/2026

A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most from screening, with those in the top CH-AI risk decile showing a number-needed-to-screen of just 43 per year.

Cardiology Neurology news

Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial

By MedXY 04/05/2026

Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Persistent AF, however, confers approximately double the risk of adverse outcomes compared with paroxysmal AF.

Cardiology news

Pulsed Field Ablation Matches Radiofrequency in Efficacy but Shows Superior Safety Profile for Paroxysmal Atrial Fibrillation: BEAT PAROX-AF Trial

By MedXY 04/05/2026

The BEAT PAROX-AF trial demonstrates equivalent single-procedure success rates between pulsed field ablation (77.2%) and radiofrequency ablation (77.6%) for paroxysmal atrial fibrillation, while showing a numerically lower safety event rate with PFA (3.4% vs 7.6%).

Cardiology Internal Medicine news

Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial

By MedXY 03/20/2026

This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel therapeutic target for atrial arrhythmias.

Cardiology Hematology-Oncology news

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY 03/12/2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.

Cardiology Diabetes & Endocrinology news

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk

By MedXY 03/07/2026

Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase the risk of atrial fibrillation and stroke in older adults.

Clinical Updates Neurology news

Rethinking Rhythm Control for Secondary Stroke Prevention: Insights from the STABLED Randomized Clinical Trial

By MedXY 03/06/2026

This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.

Cardiology news

High-Repetition-Frequency Nanosecond Pulsed Field Ablation for Paroxysmal Atrial Fibrillation: 12-Month Outcomes From the SCENA-AF Trial

By MedXY 03/03/2026

The SCENA-AF trial highlights the efficacy of nanosecond pulsed field ablation (nsPFA) for treating paroxysmal atrial fibrillation, achieving an 88.49% success rate at 12 months with minimal complications and a significant shift toward local anesthesia.

Cardiology Clinical Updates news

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial

By MedXY 03/03/2026

The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.

Cardiology Neurology news

Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial

By MedXY 03/02/2026

The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a recent history of ischemic stroke.

Cardiology news

Integrating Serum Metabolomics and Polygenic Risk Scores Redefines 5-Year Atrial Fibrillation Prediction

By MedXY 03/01/2026

A massive UK Biobank study demonstrates that combining serum metabolomics with polygenic risk scores and clinical data significantly improves the prediction of incident atrial fibrillation, identifying key metabolic markers like linoleic acid that enhance traditional risk stratification tools.

Cardiology Neurology news

NOACs Superior to Warfarin for Systemic Embolic Events: Lessons from a 71,683-Patient Meta-Analysis

By MedXY 02/28/2026

A large-scale individual patient data meta-analysis reveals that while systemic embolic events are less common than strokes in atrial fibrillation, they carry an equivalent mortality risk. NOACs significantly reduce this risk by 29% compared to warfarin, especially in high-risk phenotypes.

Cardiology news Nursing & care

Nurse-Led Integrated Care Slashes Recurrence and Boosts Quality of Life After Atrial Fibrillation Ablation

By MedXY 02/28/2026

The NURSECAT-AF trial demonstrates that structured nurse-led care significantly improves quality of life and reduces arrhythmia recurrence and emergency visits by 80% in patients undergoing their first catheter ablation for atrial fibrillation.

Cardiology Internal Medicine news

Caffeinated Coffee Linked to 39% Lower Risk of Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

By MedXY 02/09/2026

The DECAF randomized trial challenges the traditional view of caffeine as a trigger for atrial fibrillation, demonstrating that coffee consumption significantly reduces arrhythmia recurrence after cardioversion compared to total abstinence.